OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CRRX58

CareRx Corp

Drug RetailersVerified

CareRx Corp maintains a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing, while its current ratio of 1.06 suggests limited short-term liquidity cushion. The company's liquidity position is assessed as medium risk, with free cash flow of 34.9 million CAD and operating cash flow of 30.8 million CAD, but net cash is negative after subtracting total debt. This implies that the company may need to manage its debt obligations carefully to maintain financial flexibility. Profitability metrics show a return on equity of 23.86% and a return on assets of 10.75%, both of which are strong indicators of efficient capital use and asset management. These figures suggest that CareRx Corp is generating solid returns relative to its equity and asset base, which is a positive sign for investors. The company's operating income of 10.1 million CAD and net income of 26.1 million CAD further support its profitability. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, but its primary business activity is drug retailing, which is likely to be concentrated in its domestic market. The lack of segment-specific revenue data limits the ability to assess geographic or product diversification. The company's growth trajectory is not explicitly outlined in the available data, but its current financial performance suggests a stable and profitable operation. Analysts have provided a mean price target of 5.38 CAD, with a median of 5.38 CAD, and all six recommendations are categorized as "buy". This indicates a generally positive outlook from the investment community, though no specific growth projections are provided in the input data. Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in maintaining liquidity under stress scenarios. However, the dilution risk is assessed as low, and no adjustments to valuation have been applied, suggesting that the company is not currently facing significant equity issuance pressures. Recent events and filings are not detailed in the input data, but the company's financial performance and analyst recommendations suggest a stable and well-managed business. The absence of recent events or transcripts does not detract from the overall positive assessment of the company's current financial health.

30-day price · CRRX-0.12 (-3.5%)
Low$3.42High$3.90Close$3.47As of16 May, 00:00 UTC
Profile
CompanyCareRx Corp
TickerCRRX.TO
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. CareRx Corp operates in the drug retailing industry, generating revenue primarily through the sale of prescription medications, over-the-counter drugs, and related health products.

Classification. CareRx Corp is classified under the Consumer Non-Cyclicals economic sector, specifically in the Food & Drug Retailing business sector and Drug Retailers industry, with a classification confidence of 0.92.

CareRx Corp maintains a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing, while its current ratio of 1.06 suggests limited short-term liquidity cushion. The company's liquidity position is assessed as medium risk, with free cash flow of 34.9 million CAD and operating cash flow of 30.8 million CAD, but net cash is negative after subtracting total debt. This implies that the company may need to manage its debt obligations carefully to maintain financial flexibility. Profitability metrics show a return on equity of 23.86% and a return on assets of 10.75%, both of which are strong indicators of efficient capital use and asset management. These figures suggest that CareRx Corp is generating solid returns relative to its equity and asset base, which is a positive sign for investors. The company's operating income of 10.1 million CAD and net income of 26.1 million CAD further support its profitability. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, but its primary business activity is drug retailing, which is likely to be concentrated in its domestic market. The lack of segment-specific revenue data limits the ability to assess geographic or product diversification. The company's growth trajectory is not explicitly outlined in the available data, but its current financial performance suggests a stable and profitable operation. Analysts have provided a mean price target of 5.38 CAD, with a median of 5.38 CAD, and all six recommendations are categorized as "buy". This indicates a generally positive outlook from the investment community, though no specific growth projections are provided in the input data. Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in maintaining liquidity under stress scenarios. However, the dilution risk is assessed as low, and no adjustments to valuation have been applied, suggesting that the company is not currently facing significant equity issuance pressures. Recent events and filings are not detailed in the input data, but the company's financial performance and analyst recommendations suggest a stable and well-managed business. The absence of recent events or transcripts does not detract from the overall positive assessment of the company's current financial health.
Key takeaways
  • CareRx Corp generates strong returns on equity and assets, with ROE at 23.86% and ROA at 10.75%.
  • The company's liquidity position is moderate, with a current ratio of 1.06 and free cash flow of 34.9 million CAD.
  • Analysts have provided a positive outlook, with all six recommendations categorized as "buy" and a mean price target of 5.38 CAD.
  • The company's debt-to-equity ratio of 0.71 indicates a balanced capital structure with moderate leverage.
  • CareRx Corp's net cash position is negative after subtracting total debt, which could pose liquidity challenges in the future.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCAD
Revenue$370.2M
Gross profit$111.0M
Operating income$10.1M
Net income$26.1M
R&D
SG&A
D&A
SBC
Operating cash flow$30.8M
CapEx-$8.3M
Free cash flow$34.9M
Total assets$242.9M
Total liabilities$133.4M
Total equity$109.5M
Cash & equivalents$13.9M
Long-term debt$77.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$109.5M
Net cash-$64.0M
Current ratio1.1
Debt/Equity0.7
ROA10.8%
ROE23.9%
Cash conversion1.2%
CapEx/Revenue-2.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricCRRXActivity
Op margin2.7%3.1% medp25 1.2% · p75 6.8%below median
Net margin7.1%2.0% medp25 0.7% · p75 4.1%top quartile
Gross margin30.0%26.1% medp25 17.2% · p75 32.0%above median
CapEx / revenue-2.2%-2.5% medp25 -4.6% · p75 -1.4%above median
Debt / equity71.0%56.0% medp25 16.8% · p75 121.1%above median
Observations
IR observations
Mean price target5.38 CAD
Median price target5.38 CAD
High price target6.25 CAD
Low price target4.50 CAD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count6.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.17 CAD
Last actual EPS0.41 CAD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-15 14:48 UTC#37f5ba80
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:07 UTCJob: 6c067740